Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044356 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Allovectin-7® for Metastatic Melanoma
A Phase 2 study of Melanoma and Metastatic Melanoma, sponsored by Vical.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 16
- Study locations
NCT00044356 is a Phase 2 study of Melanoma and Metastatic Melanoma that has completed, run by Vical. The registered enrollment target is 133 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT00044356, a Phase 2 study of Melanoma and Metastatic Melanoma, has completed, sponsored by Vical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Conditions Studied
Interventions
- GENETIC Allovectin-7®
Study Locations (16)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- University of California, San Francisco - San Francisco
Minnesota
- North Memorial Health Care - Robbinsdale
- Mayo Clinic - Rochester
Arizona
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas Cancer Research Center - Little Rock
Colorado
- University of Colorado Cancer Center - Denver
Illinois
- Oncology Specialists, S.C. - Park Ridge
Louisiana
- Louisiana State University Medical Center - New Orleans
Maryland
- Hematology Oncology Associates of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2001-02 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044356
The ClinicalTrials.gov registry entry for NCT00044356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower). The listed sponsor is Vical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Allovectin-7® is the first listed.
NCT00044356 reports 16 study locations spanning 14 distinct geographic areas - top geographies include California, Minnesota, Arizona.
Frequently Asked Questions
What is clinical trial NCT00044356 about?
NCT00044356 is a clinical study titled "Phase II Trial of Allovectin-7® for Metastatic Melanoma". The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
What is the current status of trial NCT00044356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2001-02. Estimated completion is 2004-09.
What conditions does trial NCT00044356 study?
This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Skin Cancer, Malignant Melanoma.
What interventions are being tested in trial NCT00044356?
The interventions under investigation include: Allovectin-7® (GENETIC).
Who is sponsoring clinical trial NCT00044356?
This trial is sponsored by Vical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00044356 being conducted?
This trial has 16 study locations across Arizona, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.